| Abstract |
[Abstract] Objective To analyze the changes in neurotransmitter levels and the efficacy of aripiprazole in children with comorbidity of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). Methods According to the coin toss method, 97 children with ASD and ADHD comorbidities were divided into two groups: risperidone group, 48 cases and aripiprazole group, 49 cases, risperidone group received oral risperidone treatment Patients in the aripiprazole group were treated with aripiprazole orally, and the serum neurotransmitter levels, symptom improvement, clinical efficacy, and drug safety were compared between the two groups before and after treatment. Results After 6 weeks of treatment, CRSR-H, ADHD-RS, CRSR-I scores and 5-HT levels in the aripiprazole group were lower than those in the risperidone group, and NE and DA levels were higher than those in the risperidone group (P<0.05) ; After 12 weeks of treatment, the clinical efficacy, 5-HT, DA, NE levels, CRSR-H, CRSR-I, and ADHD-RS scores of the aripiprazole group were not statistically significant (P>0.05); aripiprazole The incidence of adverse reactions in the risperidone group was lower than that in the risperidone group (P<0.05). Conclusion The effect of aripiprazole in the treatment of children with ASD and ADHD comorbidities is equivalent to that of risperidone, but aripiprazole has the advantages of quick onset and high safety. Its therapeutic mechanism is related to the regulation of neurotransmitter levels.
|